PTEN Hamartoma Tumor Syndrome
An inherited PTEN gene disorder with benign growths and raised cancer risk
Quick Facts
- Type: Inherited (genetic) tumor predisposition syndrome
- Cause: Changes (mutations) in the PTEN gene
- Hallmark: Hamartomas (benign growths) in multiple tissues
- Key concern: Increased lifetime risk of breast, thyroid, and other cancers
Overview
PTEN hamartoma tumor syndrome (PHTS) is an umbrella term for several inherited conditions caused by changes in a gene called PTEN. The PTEN gene normally helps control how cells grow and divide, acting as a brake on excessive cell growth. When this gene is altered, cells can grow in a disorganized way, producing benign (noncancerous) growths called hamartomas and raising the lifetime risk of certain cancers.
PHTS includes several named patterns that doctors once treated as separate disorders, including Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Because they share the same underlying gene change, they are now grouped together. The condition varies widely from person to person, even within the same family.
Symptoms
Features differ greatly between people. Common findings include:
- Small noncancerous skin growths, especially around the mouth, nose, and ears
- A larger-than-average head size (macrocephaly), often present from childhood
- Noncancerous growths (polyps) in the digestive tract
- Thyroid nodules or an enlarged thyroid
- Benign breast lumps (fibrocystic changes)
- Developmental differences or learning challenges in some children
Many features are subtle, so the syndrome is sometimes recognized only after a person develops a tumor or has genetic testing for another reason.
Causes
PHTS is caused by a change (mutation) in the PTEN gene. This gene provides instructions for a protein that limits cell growth. When the protein does not work properly, cells can multiply too freely, leading to hamartomas and a higher chance of cancer.
The condition is inherited in an autosomal dominant pattern, which means a person needs only one altered copy of the gene to be affected. A parent with PHTS has a 50 percent chance of passing the gene change to each child. In some people, the gene change appears for the first time and is not inherited from a parent.
Risk Factors
- A parent, sibling, or child with a confirmed PTEN gene change
- A personal or family history of multiple hamartomas or polyps
- A personal or family history of breast, thyroid, uterine, or kidney cancer at a young age
- Macrocephaly combined with skin findings or developmental differences
PHTS is not caused by lifestyle, diet, or anything a person did. It is determined by genetics.
Diagnosis
Diagnosis usually combines clinical features with genetic testing:
- Genetic testing: A blood or saliva test looks for a change in the PTEN gene and confirms the diagnosis.
- Physical examination: A doctor checks for skin growths, head size, thyroid enlargement, and other signs.
- Imaging and scopes: Ultrasound, mammography, or colonoscopy may be used to look for growths and to begin cancer screening.
A genetics specialist or genetic counselor often coordinates testing and explains what the results mean for the person and their relatives.
Treatment
There is no cure that removes the gene change, so care focuses on early detection and treating problems as they arise.
- Regular cancer screening: Increased surveillance, such as breast imaging, thyroid ultrasound, and colon screening, helps catch cancers early when they are most treatable.
- Removing problematic growths: Hamartomas or polyps that cause symptoms, bleed, or look concerning may be removed.
- Treating cancers promptly: Any cancer that develops is treated with standard approaches such as surgery, medication, or other therapies.
- Coordinated specialist care: A team may include dermatology, endocrinology, gastroenterology, and oncology.
Screening schedules are tailored to age and personal history, so people should follow a plan made with their care team.
Prevention
The gene change itself cannot be prevented, but complications can be reduced through:
- Following the recommended cancer screening schedule closely
- Reporting new lumps, skin changes, or bowel symptoms promptly
- Genetic counseling for family members to identify who else may carry the gene change
- Maintaining general healthy habits such as not smoking and staying active
When to See a Doctor
See a doctor or genetic counselor if you have a family history of PHTS, multiple hamartomas, or early-onset cancers. Seek prompt evaluation for:
- A new or changing breast or thyroid lump
- Unexplained rectal bleeding or a change in bowel habits
- Unusual skin growths that bleed or grow quickly
Early reporting allows screening and treatment to begin sooner.
Frequently Asked Questions
Is PTEN hamartoma tumor syndrome a type of cancer?
No. PHTS is an inherited condition that increases the lifetime risk of certain cancers, but it is not cancer itself. Most growths it causes are benign hamartomas. Regular screening helps detect any cancer early.
Can PTEN hamartoma tumor syndrome be inherited?
Yes. It follows an autosomal dominant pattern, so a parent with the gene change has a 50 percent chance of passing it to each child. Sometimes the change appears for the first time in a person without a family history.
What cancers are associated with PHTS?
PHTS is linked to higher lifetime risks of breast, thyroid, uterine, kidney, and colon cancers, among others. Screening schedules are tailored to age and personal history to catch these early.
How is PHTS diagnosed?
Diagnosis combines clinical features such as skin growths and macrocephaly with genetic testing that confirms a change in the PTEN gene. A genetic counselor usually guides testing and family screening.
Does everyone with the PTEN gene change get the same symptoms?
No. Features vary widely even within the same family. Some people have prominent growths and others have few obvious signs, which is why genetic testing and regular screening are important.
References
- National Cancer Institute (NCI). PTEN Hamartoma Tumor Syndrome.
- MedlinePlus, U.S. National Library of Medicine. PTEN hamartoma tumor syndrome.
- Genetic and Rare Diseases Information Center (GARD). PTEN hamartoma tumor syndrome.
- National Organization for Rare Disorders (NORD). PTEN Hamartoma Tumor Syndrome.